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The serious increase in the prevalence of extended-
spectrum beta-lactamases (ESBLs) worldwide creates a
need for effective and easy to perform screening methods
for detection [1]. The use of an ESBL screening agar would
allow rapid recognition and isolation of ESBL-producing
bacteria. The currently available screening agars have low
specificity, mainly due to growth of species with inducible
AmpC beta-lactamases [2, 3]. The inhibition of AmpC
beta-lactamases by cloxacillin is used in ESBL confirma-
tion tests [4]; however, to the best of our knowledge,
cloxacillin for ESBL screening has not been described. We
developed an ESBL screening agar (ESA), which contains
cloxacillin to inhibit growth of AmpC-producing species
and vancomycin to inhibit growth of Enterococci, and
compared it with the commercially available, selective
medium for screening of presumptive ESBL Enterobacter-
iaceae, namely, BLSE agar (AES Laboratory, France).
The ESA consists of two MacConkey agars: one
containing ceftazidime 1.0 mg/l, and the other cefotaxime
1.0 mg/l, cloxacillin 400 mg/l, and vancomycin 64 mg/l.
The BLSE agar is a commercial double-plate agar (Mac-
Conkey with ceftazidime 2 mg/l and Drigalski with
cefotaxime 1.5 mg/l). The combined screening with
cefotaxime and ceftazidime has been shown to yield the
best sensitivity and specificity for ESBL detection [5]. The
concentration of cefotaxime and ceftazidime in ESA is
consistent with the guidelines of the Clinical and Labora-
tory Standards Institute (CLSI) for screening of ESBL-
producing Enterobacteriaceae [6] and with the guideline of
the Dutch society for medical microbiology for screening
and confirmation of ESBLs in Enterobacteriaceae (www.
nvmm.nl). The inhibition of AmpC with cloxacillin
depends on the concentration of cloxacillin in the agar
(Fig. 1). Therefore, we evaluated the performance of ESA
with different cloxacillin concentrations (400, 600, 800 and
1000 mg/l), whereby 400 mg/l yielded the most optimal
sensitivity.
The ESA and the BLSE agar were evaluated with 208
Enterobacteriaceae isolates, 70 of them were ESBL-
producers (37 Escherichia coli,1 0Klebsiella spp., 1
Proteus mirabilis,2 0Enterobacter spp., 2 Citrobacter
freundii) and 138 were ESBL negative (43 E. coli,1 7
Klebsiella spp., 9 Proteus mirabilis,5 5Enterobacter spp., 6
Citrobacter freundii,4Morganella morganii,1Providencia
spp., 3 Serratia spp.). These isolates had previously been
genotypically characterized with PCR and subsequent
sequence analysis with SHV, TEM and CTX-M primers
for the blaSHV, blaTEM, and blaCTX-M genes [7, 8]. The
media were incubated in air at 37°C for 18 to 24 h. For
negative cultures the incubation was prolonged for 48 h.
The sensitivity and specificity of the ESA and the BLSE
agar tested with the 208 Enterobacteriaceae isolates were
100% (70/70) and 84.7% (117/138), respectively, for the
ESA, and 100% (70/70) and 57.2% (79/138) for the BLSE
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e-mail: n.alnaiemi@vumc.nlagar. The prolongation of incubation did not improve the
sensitivity of the ESA or BLSE agars. The better
performance of the ESA was mainly due to less false
positive results due to AmpC-producing strains, especially
Enterobacter spp. (false positive results for Enterobacter
spp. with ESA was 29% or 16/55 and with BLSE was 89%
or 49/55). The specificity of ESA for screening of ESBL-
producing strains was significantly better than the speci-
ficity of BLSE agar, which reduced the number of
unnecessary confirmations. A quick and easy to use
screening method to facilitate the detection of ESBL-
producing Enterobacteriaceae in clinical settings is very
important for optimal therapy and early application of
appropriate infection control measures.
The ESA is, however, intended as a screening tool;
therefore, it is important to note that any growth on the
plates should not be taken as definitive proof of ESBL
production, which can only be achieved by use of
appropriate confirmatory tests. Despite the limitations of
this preliminary study, our results show that ESA is a
sensitive and convenient method to screen for ESBL-
producing organisms. Further evaluation should be made
with clinical specimens originating directly from human
carries.
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Fig. 1 AmpC inhibition with
cloxacillin. Citrobacter freundii,
AmpC positive, ESBL negative.
The increase in the zone around
AM+CL and CFOXT with
addition of cloxacillin to the
MH indicates the inhibition of
AmpC. R, resistant; I,
intermediate susceptible; S,
susceptible; AM+CL,
amoxicillin-clavulanate;
CFOXT, cefoxitin
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